Studies have shown that active fund managers routinely underperform the S&P500 index*​

Design Therapeutics, Inc. (NASDAQ: DSGN)

DSGN Stock Predictions and Ratings

WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
51.60%

DSGN Stock Analysis

DSGN PE Ratio:

DSGN PEG Ratio: Not Available

DSGN Forward EPS Growth (12 month): 0.00%

DSGN PS Ratio:

DSGN PSG Ratio: Not Available

DSGN Forward Revenue Growth (12 month): 0.00%

DSGN Articles

No data was found